Drug profile · INN
ondansetron
APX-ONDANSETRON
ondansetron (APX-ONDANSETRON) is a serotonin 3a (5-ht3a) receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — ondansetron
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 6
- Programs
- 27
- Data quality
- 0.89
Quick answer
ondansetron (APX-ONDANSETRON) is a serotonin 3a (5-ht3a) receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Serotonin 3a (5-HT3a) receptor antagonist
Primary target: 5-hydroxytryptamine receptor 3A
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 11273131
Pharmaceutical compositions with enhanced permeation
granted -
US 11129799
Dual lane coating
granted -
US 10947033
Reduction in stress cracking of films
granted -
US 10464739
Reduction in stress cracking of films
granted -
US 10034833
Sublingual and buccal film compositions
granted -
US 9675588
Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
granted
Frequently asked questions
What is ondansetron?
ondansetron (APX-ONDANSETRON) is a serotonin 3a (5-ht3a) receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for ondansetron?
APX-ONDANSETRON is a marketed brand name for ondansetron. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ondansetron?
ondansetron has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.